Initial clinical results confirm that PQR309 is well tolerated and shows first signs of clinical antitumor activity. PIQUR presented five posters at the American Association for Cancer Research (AACR) Annual Meeting.
Initial results from the first-in-man phase 1 trial indicate that PQR309 is safe and well-tolerated with no significant side effects. „In addition to the good safety data, PQR309 has also shown the first encouraging signs of clinical activity in solid tumors. With these promising initial clinical results of PQR309, we are making an important step towards our vision to help patients to survive cancer”, commented Dr. Vladimir Cmiljanovic, CEO of PIQUR Therapeutics AG. The company and its academic collaborators presented five posters highlighting preclinical as well as clinical data on PQR309 at the AACR Annual Meeting, which took place in Philadelphia last week.
PIQUR’s lead compound, PQR309, is a potent and balanced pan-PI3K/mTOR inhibitor with excellent prospects to become a powerful anti-cancer drug. PQR309 compares favorably to current and clinically most advanced pan-PI3K/mTOR inhibitors with respect to the off-target effects and drug-like properties. Unlike most of its competitors, PQR309 crosses the blood-brain barrier, expanding its use beyond solid tumors and lymphomas and into brain cancers. PQR309 showed activity in different aggressive cancer cell lines inhibiting the PI3K/mTOR pathway. PIQUR has successfully concluded the first-in-man phase 1 study in Europe; the maximum tolerated dose (MTD) was determined and the results indicated first evidence of clinical antitumor activity. The full results of the phase 1 trial are anticipated in the second quarter of 2015 after completion of the ongoing expansion study in USA.
Please login or sign up to comment.
Commenting guidelines